Ptc Therapeutics (PTCT) Common Equity (2012 - 2026)

Ptc Therapeutics' Common Equity history runs 15 years deep, the most recent figure standing at -$180.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 2.85% year-over-year to -$180.5 million in Q1 2026; TTM through Mar 2026 was -$180.5 million, a 2.85% increase from a year earlier, with the FY2025 full-year figure at -$205.3 million, up 81.3% from the prior year.
• Common Equity climbed to -$180.5 million in Q1 2026 per PTCT's latest filing, from -$205.3 million in the prior quarter.
• Across five years, Common Equity topped out at -$90.6 million in Q1 2022 and bottomed at -$1.1 billion in Q4 2024.
• The 5-year median for Common Equity is -$347.1 million (2022), against an average of -$490.2 million.
• Across the five-year window, Common Equity slumped 24236.72% in 2022 and soared 85.23% in 2025, its largest moves.
• Year by year, Common Equity stood at -$347.1 million in 2022, then slumped by 135.84% to -$818.6 million in 2023, then slumped by 34.15% to -$1.1 billion in 2024, then soared by 81.3% to -$205.3 million in 2025, then increased by 12.1% to -$180.5 million in 2026.
• Per Business Quant, the three latest PTCT Common Equity figures stand at -$180.5 million (Q1 2026), -$205.3 million (Q4 2025), and -$155.8 million (Q3 2025).